Page 1

Ⓒ immunovia INTERIM REPORT JANUARY JUNE SEK thousands unless otherwise stated Net sales Operating earnings Earnings before tax Net earnings Earnings per share before dilution ( SEK ) Earnings per share before after dilution ( SEK ) Equity ratio ( % ) Number of shares at the end of the period 2021 Key indicators 2021 April - June - 38 -46,731 -49,261 -49,261 -2.18 -2.18 87 22,631,581 Significant events April - June 2021 IMMray ™ PanCan - d was highlighted at a seminar orga nized by the largest patient organization in the US , the Pancreatic Cancer Action Network . Dr. Rosalie C. Sears , Co - Director of the Brenden - Colson Center for Pancreatic Care and Professor at Oregon Health & Science Universi ty , as well as advisor to PANCAN , expressed her enthusi asm for the test's accurate ability to detect early stage I and II pancreatic cancer . As a result of the updated guidelines from US Preventive Services Task Force ( USPSTF ) , National Comprehensive Cancer Network ( NCCN ) , American Society of Clinical On cology ( ASCO ) , and the International Cancer of the Pan creas Screening ( CAPS ) , Immunovia presented an updated assessment of the total market size for familial / heredi tary pancreatic cancer risk group in the US . Immunovia's new estimate shows that 315,000 - 350,000 individuals have a familial / hereditary risk of pancreatic cancer and would qualify to be included in surveillance programs . Immunovia recapped its road to reimbursement for IMMrayTM PanCan - d that will be launched as a laboratory developed test ( LDT ) in the US . Immunovia will start by exploring a positive Medicare coverage and the aim is to obtain coverage and reimbursement agreements with a majority of US payers prior to year - end 2022 . IMMUNOVIA AB Immunovia , Inc. received a CLIA Certificate of Registra tion ( CLIA Number : 22D2227265 ) , which is a prerequisite to receiving a clinical laboratory licensure - the Massa chusetts State approval that was received after the end of the period ( see below ) . 2020 April - June 159 -28,686 -34,099 -34,099 -1.67 1.67 92 2021 Jan - June Ⓒ 161 -75,813 -72,707 -72,496 -3.21 -3.21 87 22,603,081 22,631,581 2020 Jan - June 173 -60,800 -61,850 -61,850 -3.08 -3.08 92 22,603,081 EARLY DETECTION 2020 Full year 362 -134,343 -146,033 -146,033 -6.84 -6.84 91 Immunovia hosted a key opinion leader event on the clinical need and use of IMMrayTM PanCan - d . Three prominent experts participated and presented their view : Dr. Stephen Pereira , Professor of Hepatology and Gastro enterology , University College London , Dr. James Farrell , Professor of Medicine at Yale School of Medicine and Director of the Yale Center for Pancreatic Diseases at Yale New Haven Health , and Dr. Geoffrey Burns , MD , FAAFP , Renaissance Family Medicine of Wellesley , Massachusetts , USA . 22,631,581 Significant events after the period On August 3 , Immunovia Inc. received a clinical labo ratory licensure from the Massachusetts Department of Public Health . This means that Immunovia Inc. has been approved to begin commercial patient testing with the IMMrayTM PanCan - d Test in the US , exclusively through the laboratory in Marlborough , Massachusetts . Immunovia provided two updates regarding the IMM ray ™ PanCan - d test . First , the test is being launched at a list price of USD 995 per test . Second , the test is launched for those individuals with CA 19-9 levels greater than 2.5 U / ml . The overall sensitivity of the test then improves to 89 percent in stages I and II and 92 percent in all stages . The specificity of the test is 99 percent .